Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001213900-26-053404
Filing Date
2026-05-07
Accepted
2026-05-07 17:01:25
Documents
2
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 18327
2 JOINT FILING AGREEMENT ea028970501ex99-a.htm EX-99.A 13747
  Complete submission text file 0001213900-26-053404.txt   33795
Mailing Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-624-1100
RIGEL PHARMACEUTICALS INC (Subject) CIK: 0001034842 (see all company filings)

EIN.: 943248524 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-59985 | Film No.: 26954687
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 104 FIELD POINT ROAD 2ND FLOOR GREENWICH CT 06830
Business Address 104 FIELD POINT ROAD 2ND FLOOR GREENWICH CT 06830 4752083111
Soleus Capital Master Fund, L.P. (Filed by) CIK: 0001812275 (see all company filings)

EIN.: 981413657 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G